A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321
Recruiting
The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: Clinical Trial Site, Los Angeles, California +5 locations
Conditions: Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Register for Updates
Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial
NCT06671002
Recruiting
This trial is being completed to compare two commonly used options to treat pain after discharge from surgery. Participants that undergo tonsil removal, gallbladder removal, and knee scope will be eligible to enroll. Eligible participants will be randomized to prescription of 1 of 2 groups of medications (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) plus acetaminophen or low dose opioids with the NSAIDs plus acetaminophen. The key question the study seeks to answer is which option will have th... Read More
Gender:
ALL
Ages:
Between 12 years and 20 years
Trial Updated:
04/15/2025
Locations: Children's Hospital Los Angeles (CHLA), Los Angeles, California +3 locations
Conditions: Surgery, Pain, Post Operative
Register for Updates
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
NCT06716580
Recruiting
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
04/15/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +5 locations
Conditions: Lung Cancer, EGFR Gene Mutation
Register for Updates
Prehabilitation for Kidney Transplant Candidates
NCT06886256
Recruiting
This interventional trial seeks to determine the feasibility of wearable sensors to provide data from patients while undergoing supervised exercise.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/15/2025
Locations: Houston Methodist Hospital System, Houston, Texas
Conditions: Kidney Transplantation, Frailty, Chronic Kidney Insufficiency
Register for Updates
Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System
NCT06931561
Recruiting
The purpose of this study is to further understand the clinical impact and follow-up steps that may be required based on using whole-body Magnetic Resonance Imaging (MRI) or whole-body ultrasound and blood tests to detect multiple cancers in firefighters. This study involves an investigational test (cancer blood test) that has not been approved by the U.S. Food and Drug Administration (FDA). Whole-body MRI and whole-body ultrasound are approved by the U.S. Food and Drug Administration (FDA) to... Read More
Gender:
ALL
Ages:
Between 35 years and 85 years
Trial Updated:
04/15/2025
Locations: Inova Schar Cancer - Saville Cancer Screening and Prevention Center, Fairfax, Virginia
Conditions: Cancer
Register for Updates
Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans
NCT06940895
Recruiting
The purpose of this study is to demonstrate the safety and efficacy of Sirolimus 0.2% topical gel for patients with Acanthosis Nigricans
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: New York Harbor VA Brooklyn Campus, Brooklyn, New York
Conditions: Acanthosis Nigricans
Register for Updates
Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies
NCT01109394
Recruiting
Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, additional samples will be collected from children and adults who have been diagnosed with common childhood cancers such as leukemia and tumors of the central nervous system. Objectives: - To collect and st... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
04/15/2025
Locations: Children's National Medical Center, Washington, District of Columbia +4 locations
Conditions: Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, Renal Cancer
Register for Updates
Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT03564340
Recruiting
The main purpose of this study is to: * Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of REGN4018 and/or cemiplimab in your body and measure how well your body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that REGN4018 alone or with cemiplimab can treat recurrent advanced ovarian... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/15/2025
Locations: University of Alabama_6th Ave, Birmingham, Alabama +51 locations
Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer
Register for Updates
Dysvascular Amputation Self-Management of Health
NCT04083456
Recruiting
The purpose of this study is to determine if walking biobehavioral intervention improves physical activity after dysvascular lower limb amputation.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
04/15/2025
Locations: University of Colorado Hospital, Aurora, Colorado
Conditions: Amputation, Diabetes Mellitus, Peripheral Artery Disease
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: University of Alabama at Birmingham (UAB) - Children's of Alabama, Birmingham, Alabama +13 locations
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates
Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder
NCT04798274
Recruiting
Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental syndrome. Researchers think brain development may be controlled by gamma-aminobutyric acid (GABA). They want to learn how abnormalities in the GABA system may contribute to ASD. Objective: To see if repetitive transcranial magnetic stimulation (rTMS) creates short-term changes in how different parts of the brain communicate. Eligibility: Right-handed people ages 14-17 with ASD, and healthy volunteers ages 18-25. Des... Read More
Gender:
ALL
Ages:
Between 14 years and 25 years
Trial Updated:
04/15/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Autism Spectrum Disorder
Register for Updates
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: * Study duration: 36 weeks * Treatment duration: 24 weeks * Visit frequency: every 2 weeks
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Accel Research Sites Network - Birmingham- Site Number : 8400003, Birmingham, Alabama +70 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates